NCT04193826已完成不适用
The Conformal Prague Study: An Evaluation of the Safety and Performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Freedom From Major Adverse Events
研究概览
简要总结
A prospective, single center, open-label, single arm, study to evaluate the safety and technical performance of the CLAAS system for closure of the left atrial appendage.
详细描述
The primary objective of the study is to evaluate feasibility of ICE as primary imaging modality for device success in patients with non-valvular atrial fibrillation at increased risk for stroke and systemic embolism who are recommended for oral anticoagulation (OAC) therapy but have an appropriate rationale to seek a non-pharmacological alternative to OAC. TEE will be used to confirm the ICE evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant female aged ≥18 years
- •Documented non-valvular AF (paroxysmal, persistent, or permanent)
- •High risk of stroke or systemic embolism, defined as a CHA2DS2-VASc score of ≥ 2
- •The patient is recommended for oral anticoagulation therapy (OAC), but has an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation
- •The patient is willing and able to comply with the protocol-specified medication regimen and follow-up evaluations
- •The patient (or legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Ethics Committee (EC)
排除标准
- •Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
- •Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., prior atrial septal defect [ASD] or patent foramen ovale [PFO], surgical repair or implanted closure device, or obliterated or ligated left atrial appendage)
- •Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- •Patients with a medical condition (other than atrial fibrillation) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve)
- •History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated
- •Active infection with bacteremia
- •Documented symptomatic carotid artery disease (>50% diameter stenosis with prior ipsilateral stroke or TIA) or known asymptomatic carotid artery disease (diameter stenosis of >70%)
- •Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or non-cardiac interventional or surgical procedure
- •Recent (within 90 days of index procedure) stroke, transient ischemic attack
- •Recent myocardial infarction within 60 days of index procedure
- •Vascular access precluding delivery of implant with catheter-based system
- •Severe heart failure (New York Heart Association Class III or IV)
- •Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any mechanical valve implant
- •Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation), or dialysis at the time of screening
- •Platelet count <100,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3
- •Patient has a known allergy, hypersensitivity or contraindication to aspirin, heparin, clopidogrel, prasugrel, ticagrelor, or device materials (e.g., nickel, titanium, gold), or the patient has contrast sensitivity that cannot be adequately pre-medicated
- •Current participation in another investigational drug or device study that interferes with this study
- •Patient is a prisoner
- •Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year
- •Patient has a condition which precludes adequate transesophageal echocardiographic (TEE) assessment
结局指标
主要结局
Freedom From Major Adverse Events
时间窗: 7 days post-procedure
Major adverse events defined as: All cause mortality, ischemic stroke, systemic thromboembolism, device or procedure-related adverse events requiring open cardiac surgery or major endovascular intervention.
Closure Success
时间窗: 45-days post-procedure
Closure success, defined as device success followed by complete closure or peri-device residual leak ≤5 mm in width
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear PalsyProgressive Supranuclear PalsySpinal Cord StimulationNCT04367116Huashan Hospital3
Unknown
不适用
The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance CriteriaCoronary Artery DiseaseNCT04617899CardioNavi MedTech (Wuhan) Co., Ltd.120
已完成
不适用
Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment AlgorithmAmetropiaNCT04617080Bausch & Lomb Incorporated60
已完成
不适用
Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I)Coronary Artery DiseaseNCT02650128Shockwave Medical, Inc.60
已完成
不适用
Clinical and Home Use Feasibility Study of a Percutaneous Optical Glucose Fiber SensorDiabetes (DM)NCT04152408EyeSense GmbH7